TY - JOUR
T1 - Advanced carcinoma of the pancreas
T2 - Phase II study of combined chemotherapy, β-interferon, and retinoids
AU - Recchia, Francesco
AU - Sica, Gigliola
AU - Casucci, Desireè
AU - Rea, Silvio
AU - Gulino, Alberto
AU - Frati, Luigi
PY - 1998/6
Y1 - 1998/6
N2 - Because of the poor response of pancreatic cancer to conventional therapy, the authors performed a phase II pilot study to evaluate whether β- interferon and retinoids, added to active chemotherapeutic agents, could increase response rate and survival in a group of patients who had metastatic disease. Twenty-three chemotherapy-naive patients were treated as follows: epirubicin, 60 mg/m2, and mitomycin C, 10 mg/m2, intravenously on day 1; folinic acid, 200 mg/m2, and 5-fluorouracil (5-FU), 370 mg/m2, intravenously for 5 consecutive days. β-Interferon, 1 x 106 IU/m2, subcutaneously three times a week, and retinol palmitate, 50,000 IU orally twice a day, were given between chemotherapy cycles. Patients having responses and disease stabilization were maintained with the same dose of β- interferon and retinol palmitate. Treatment was given every 4 weeks for four courses or until onset of progression. A median of three courses of chemotherapy was delivered to each patient. All patients were evaluable. Eight patients responded (35%) and 8 (35%) had stable disease. Median time to progression and survival for all patients were, respectively, 6.1 months and 11 months. Toxicity was severe: 60% of patients had hematologic toxicity, 40% had gastrointestinal toxicity, 13% had cardiac toxicity, and 1 patient had a hemolitic-uremic syndrome. The combination of chemotherapy, β-interferon, and retinoids shows activity in metastatic pancreatic carcinoma. Toxicity was high but patients who had responses and disease stabilization had prolonged symptom palliation.
AB - Because of the poor response of pancreatic cancer to conventional therapy, the authors performed a phase II pilot study to evaluate whether β- interferon and retinoids, added to active chemotherapeutic agents, could increase response rate and survival in a group of patients who had metastatic disease. Twenty-three chemotherapy-naive patients were treated as follows: epirubicin, 60 mg/m2, and mitomycin C, 10 mg/m2, intravenously on day 1; folinic acid, 200 mg/m2, and 5-fluorouracil (5-FU), 370 mg/m2, intravenously for 5 consecutive days. β-Interferon, 1 x 106 IU/m2, subcutaneously three times a week, and retinol palmitate, 50,000 IU orally twice a day, were given between chemotherapy cycles. Patients having responses and disease stabilization were maintained with the same dose of β- interferon and retinol palmitate. Treatment was given every 4 weeks for four courses or until onset of progression. A median of three courses of chemotherapy was delivered to each patient. All patients were evaluable. Eight patients responded (35%) and 8 (35%) had stable disease. Median time to progression and survival for all patients were, respectively, 6.1 months and 11 months. Toxicity was severe: 60% of patients had hematologic toxicity, 40% had gastrointestinal toxicity, 13% had cardiac toxicity, and 1 patient had a hemolitic-uremic syndrome. The combination of chemotherapy, β-interferon, and retinoids shows activity in metastatic pancreatic carcinoma. Toxicity was high but patients who had responses and disease stabilization had prolonged symptom palliation.
KW - β- interferon
KW - 5-Fluorouracil
KW - Epirubicin
KW - Mitomycin C
KW - Pancreatic carcinoma
KW - Retinoids
UR - http://www.scopus.com/inward/record.url?scp=0031814703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031814703&partnerID=8YFLogxK
U2 - 10.1097/00000421-199806000-00014
DO - 10.1097/00000421-199806000-00014
M3 - Article
C2 - 9626797
AN - SCOPUS:0031814703
VL - 21
SP - 275
EP - 278
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 3
ER -